Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy. “This network ...

I f you have ulcerative colitis — a type of inflammatory bowel disease (IBD) characterized by stomach pain, fatigue, urgency, and other gut symptoms — you may be familiar with the wide range of ...

Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...

Please provide your email address to receive an email when new articles are posted on . Arena Pharmaceuticals announced that etrasimod, its novel, oral selective sphingosine 1-phosphate receptor ...

Fred D. Lublin, MD, FAAN, FANA: The sphingosine-1-phosphate receptor modulators are in use now for treating MS [multiple sclerosis]. The first 1 was fingolimod, which was approved in 2010 and we’ve ...

Please provide your email address to receive an email when new articles are posted on . The management of multiple sclerosis has improved considerably over the past decade with broadening of the ...

The oral sphingosine-1-phosphate (S1P) receptor modulator ozanimod (Zeposia) was effective for induction in moderately to severely active ulcerative colitis (UC), meeting the primary endpoint in a ...

Arena Pharmaceuticals, Inc. ARNA received an upgrade from Wall Street on Wednesday as it awaits Phase 2 data for the S1P modulator etrasimod in ulcerative colitis. Wells Fargo's Jim Birchenough ...

CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...

After its obesity drug Belviq flopped, Arena Pharmaceuticals rebooted its R&D program to focus on other drugs, including etrasimod, a drug that's being studied for use in ulcerative colitis patients.

SAN DIEGO — For the treatment of relapsing multiple sclerosis (MS), ozanimod may not convey the same health risks as fingolimod, its older counterpart in the sphingosine 1-phosphate (S1P) receptor ...